$2.15 Billion is the total value of Camber Capital Management LP's 31 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MYL | Buy | MYLAN N V | $176,120,000 | +8.1% | 9,250,000 | +60.9% | 8.21% | +1.1% |
| DVA | Buy | DAVITA INC | $112,520,000 | +38.2% | 2,000,000 | +33.3% | 5.24% | +29.3% |
| BKD | Buy | BROOKDALE SENIOR LIVING | $90,125,000 | +24.5% | 12,500,000 | +13.6% | 4.20% | +16.5% |
| NKTR | Buy | NEKTAR THERAPEUTICS | $88,950,000 | +32.4% | 2,500,000 | +25.0% | 4.15% | +23.8% |
| AGN | New | ALLERGAN PLCcall | $83,715,000 | – | 500,000 | +100.0% | 3.90% | – |
| HCA | New | HCA HEALTHCARE INC | $81,102,000 | – | 600,000 | +100.0% | 3.78% | – |
| ASND | Buy | ASCENDIS PHARMA A Ssponsored adr | $74,848,000 | +47.9% | 650,000 | +51.2% | 3.49% | +38.3% |
| GILD | New | GILEAD SCIENCES INC | $67,560,000 | – | 1,000,000 | +100.0% | 3.15% | – |
| TEVA | Buy | TEVA PHARMACEUTICAL INDS LTDsponsored ads | $59,995,000 | +9.3% | 6,500,000 | +85.7% | 2.80% | +2.3% |
| ZYME | Buy | ZYMEWORKS INC | $57,200,000 | +63.2% | 2,600,000 | +20.0% | 2.67% | +52.7% |
| MYL | New | MYLAN N Vcall | $57,120,000 | – | 3,000,000 | +100.0% | 2.66% | – |
| THC | Buy | TENET HEALTHCARE CORP | $51,650,000 | +2.3% | 2,500,000 | +42.9% | 2.41% | -4.3% |
| AMAG | Buy | AMAG PHARMACEUTICALS INC | $29,970,000 | -12.2% | 3,000,000 | +13.2% | 1.40% | -17.9% |
| UTHR | New | UNITED THERAPEUTICS CORP DEL | $28,689,000 | – | 367,529 | +100.0% | 1.34% | – |
| GSK | New | GLAXOSMITHKLINE PLCsponsored adr | $20,010,000 | – | 500,000 | +100.0% | 0.93% | – |
| CYCN | New | CYCLERION THERAPEUTICS INC | $17,884,000 | – | 1,561,915 | +100.0% | 0.83% | – |
| TGTX | New | TG THERAPEUTICS INC | $8,650,000 | – | 1,000,000 | +100.0% | 0.40% | – |
| ALKS | New | ALKERMES PLC | $4,244,000 | – | 188,281 | +100.0% | 0.20% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
| BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
| PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
| TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
| NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
| UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
| MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
| SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
| MYLAN NV | 21 | Q3 2020 | 10.1% |
| AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
| Solid Biosciences Inc. | December 12, 2022 | ? | ? |
| AVROBIO, Inc. | February 14, 2022 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
| AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
| Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
| Change Healthcare Inc. | February 16, 2021 | ? | ? |
| GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
| Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
| Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-30 |
| 13F-HR | 2023-08-14 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.